Truvada (emtricitabine and tenofovir) was originally developed as an antiviral drug for managing HIV, but in 2012 the U.S. Food and Drug Administration (FDA) approved it as a daily prophylactic pill for patient populations at highest risk for HIV, such as gay men with multiple sexual partners. But many have questioned whether the drug was effective enough and also whether the prophylactic treatment might encourage risky behavior and a rise in other sexually transmitted—and highly treatable—infections. Though the drug went through the scrutiny of two large-scale clinical trials before earning approval, information about the its impact in the real world hasn’t been well known.
http://www.newsweek.com/truvada-hiv-...fective-368579
http://www.newsweek.com/truvada-hiv-...fective-368579